Bank of New York Mellon Corp raised its position in Voyager Therapeutics Inc (NASDAQ:VYGR) by 16.2% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 61,858 shares of the company’s stock after buying an additional 8,633 shares during the period. Bank of New York Mellon Corp’s holdings in Voyager Therapeutics were worth $1,274,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in VYGR. DAFNA Capital Management LLC boosted its position in Voyager Therapeutics by 187.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock valued at $1,835,000 after buying an additional 133,488 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Voyager Therapeutics by 232.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock worth $879,000 after purchasing an additional 68,574 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $1,122,000. HarbourVest Partners LLC bought a new position in shares of Voyager Therapeutics in the 2nd quarter worth $400,000. Finally, Northern Trust Corp boosted its position in shares of Voyager Therapeutics by 26.8% in the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after purchasing an additional 28,222 shares during the last quarter. Hedge funds and other institutional investors own 35.97% of the company’s stock.

Several research analysts have recently issued reports on the company. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 6th. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. BTIG Research assumed coverage on Voyager Therapeutics in a research report on Tuesday, December 19th. They issued a “buy” rating and a $32.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $28.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, November 28th. Finally, Wedbush restated an “outperform” rating and issued a $26.00 price target (up from $22.00) on shares of Voyager Therapeutics in a research report on Monday, November 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.90.

In related news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction on Monday, December 11th. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70. Following the sale, the insider now owns 10,983 shares of the company’s stock, valued at approximately $149,698.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.00% of the company’s stock.

Shares of Voyager Therapeutics Inc (VYGR) opened at $18.27 on Friday. The company has a market capitalization of $468.92 and a price-to-earnings ratio of -6.43. Voyager Therapeutics Inc has a 12 month low of $8.10 and a 12 month high of $25.99.

ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Purchases 8,633 Shares of Voyager Therapeutics Inc (VYGR)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-purchases-8633-shares-of-voyager-therapeutics-inc-vygr/1803778.html.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics Inc (NASDAQ:VYGR).

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.